The 6-month question: Can EYP-1901 rewrite DME care?

Diabetic macular edema remains one of the most treatment-intensive conditions in retina: anti-VEGF therapy works, but monthly-to-quarterly injections are hard for patients to sustain, and real-world vision outcomes routinely lag those seen in clinical trials. EYP-1901—an investigational sustained-delivery tyrosine kinase inhibitor engineered to release drug over roughly six months—aims to close that gap by providing continuous underlying suppression between office visits.

In this Q&A, Dante Pieramici, MD, a vitreoretinal specialist and co-director of research at California Retina Consultants in Santa Barbara, discusses what durable dosing could mean for clinic capacity, patient adherence, and the socioeconomic realities that cause diabetic patients to fall out of care.